A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab (bev) as a first-line therapy for patients with metastatic colorectal cancer

被引：0
|
作者：
Sato, Yasushi
Ohnuma, Hiroyuki
Hirakawa, Masahiro
Takahashi, Minoru
Osuga, Takahiro
Takada, Kohichi
Hayashi, Tsuyoshi
Sato, Tsutomu
Miyanishi, Koji
Takimoto, Rishu
Kobune, Masayoshi
Okita, Kenji
Furuhata, Tomohisa
Hirata, Koichi
Kato, Junji
机构：
[1] Sapporo Med Univ, Sch Med, Dept Med Oncol & Hematol, Sapporo, Hokkaido, Japan
[2] Sapporo Kyoritsu Gorinbashi Hosp, Div Gastroenterol, Sapporo, Hokkaido, Japan
[3] Sapporo Med Univ, Sch Med, Dept Surg Surg Oncol & Sci, Sapporo, Hokkaido, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.612
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
612
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
    Sato, Yasushi
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Minoru
    Osuga, Takahiro
    Okagawa, Yutaka
    Murase, Kazuyuki
    Takada, Kohichi
    Kawano, Yutaka
    Iyama, Satoshi
    Hayashi, Tsuyoshi
    Sato, Tsutomu
    Miyanishi, Koji
    Takimoto, Rishu
    Kobune, Masayoshi
    Okita, Kenji
    Mizuguchi, Toru
    Furuhata, Tomohisa
    Hirata, Koichi
    Kato, Junji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 587 - 594
  • [2] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
    Yasushi Sato
    Hiroyuki Ohnuma
    Masahiro Hirakawa
    Minoru Takahashi
    Takahiro Osuga
    Yutaka Okagawa
    Kazuyuki Murase
    Kohichi Takada
    Yutaka Kawano
    Satoshi Iyama
    Tsuyoshi Hayashi
    Tsutomu Sato
    Koji Miyanishi
    Rishu Takimoto
    Masayoshi Kobune
    Kenji Okita
    Toru Mizuguchi
    Tomohisa Furuhata
    Koichi Hirata
    Junji Kato
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 587 - 594
  • [3] A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study
    Sato, Yasushi
    Hirakawa, Masahiro
    Ohnuma, Hiroyuki
    Takahashi, Minoru
    Okamoto, Tetsuro
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Furuhata, Tomohisa
    Takemasa, Ichiro
    Kato, Junji
    Takayama, Tetsuji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1133 - 1139
  • [4] A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study
    Yasushi Sato
    Masahiro Hirakawa
    Hiroyuki Ohnuma
    Minoru Takahashi
    Tetsuro Okamoto
    Koichi Okamoto
    Hiroshi Miyamoto
    Naoki Muguruma
    Tomohisa Furuhata
    Ichiro Takemasa
    Junji Kato
    Tetsuji Takayama
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 1133 - 1139
  • [5] A triplet combination with oxaliplatin/capecitabine/irinotecan (XELOXIRI) plus cetuximab (Cmab) as a first-line therapy in wild-type KRAS, metastatic colorectal cancer: a dose escalating study
    Sato, Y.
    Ohnuma, H.
    Hirakawa, M.
    Kikuch, S.
    Takahashi, M.
    Okamoto, T.
    Tsuji, Y.
    Okita, K.
    Furuhata, T.
    Takemasa, I.
    Kato, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
    Zarate, R.
    Rodriguez, J.
    Bandres, E.
    Patino-Garcia, A.
    Ponz-Sarvise, M.
    Viudez, A.
    Ramirez, N.
    Bitarte, N.
    Chopitea, A.
    Gacia-Foncillas, J.
    BRITISH JOURNAL OF CANCER, 2010, 102 (06) : 987 - 994
  • [7] Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
    R Zarate
    J Rodríguez
    E Bandres
    A Patiño-Garcia
    M Ponz-Sarvise
    A Viudez
    N Ramirez
    N Bitarte
    A Chopitea
    J Gacía-Foncillas
    British Journal of Cancer, 2010, 102 : 987 - 994
  • [8] A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients
    Van Cutsem, E.
    Verslype, C.
    Beale, P.
    Clarke, S.
    Bugat, R.
    Rakhit, A.
    Fettner, S. H.
    Brennscheidt, U.
    Feyereislova, A.
    Feyereislova, A.
    Delord, J. -P.
    ANNALS OF ONCOLOGY, 2008, 19 (02) : 332 - 339
  • [9] A phase II study of capecitabine, oxaliplatin and irinotecan (XELOXIRI) as salvage therapy in patients with refractory metastatic colorectal cancer.
    Kwok, Gin Wai
    Leung, Roland Ching-Yu
    Chiu, Joanne
    Tang, Vikki
    Yau, Thomas Cheung
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
    Schmiegel, W.
    Reinacher-Schick, A.
    Arnold, D.
    Kubicka, S.
    Freier, W.
    Dietrich, G.
    Geissler, M.
    Hegewisch-Becker, S.
    Tannapfel, A.
    Pohl, M.
    Hinke, A.
    Schmoll, H. J.
    Graeven, U.
    ANNALS OF ONCOLOGY, 2013, 24 (06) : 1580 - 1587
12345